TMS denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for tms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Denied TMS as "Duplicate Therapy" — and Why That Label Deserves Challenge

A "duplicate therapy" denial from UnitedHealthcare means UHC concluded that TMS is redundant with another treatment you are currently receiving — most often another active antidepressant prescription, an active electroconvulsive therapy (ECT) authorization, or an active behavioral health benefit. This reasoning is clinically contested: TMS is frequently used alongside — not instead of — pharmacotherapy, and it operates through a distinct mechanism. The denial usually reflects a policy or coding rule rather than a clinical judgment about your specific care plan.

The basis for a duplicate-therapy denial is UHC's published coverage policy, not the FDA clearance language. TMS's clearance does not prohibit concurrent treatment with other modalities.

## The Federal Appeal Framework

Under ACA §2719, non-grandfathered plans must provide internal appeal and independent external review. Under ERISA §503, employer-sponsored plans must provide a full-and-fair review with written reasoning. An expedited appeal is available when your clinician certifies that the standard timeline would seriously jeopardize your health or ability to function. The external-review window is generally available for roughly four months after the internal denial; confirm the exact deadline in your denial letter.

## What to Gather

• UHC's published coverage policy for TMS. Request the current coverage determination document by name. Identify the precise "duplicate therapy" language and what it is keyed to.
• Your current treatment plan. A written statement from your psychiatrist describing your complete current treatment regimen and explaining why TMS serves a distinct clinical purpose that the other treatments do not.
• Diagnosis and severity documentation. Formal psychiatric records establishing the diagnosis and current symptom severity — particularly if the concurrent treatment has produced only partial response.
• Prior treatment history. Documentation of the treatment steps already taken, demonstrating that the concurrent treatment is supplemental, not curative, and that TMS is medically necessary for the residual impairment.
• Prescriber medical-necessity letter. A signed statement from your psychiatrist specifically addressing the "duplicate therapy" finding: why TMS is not duplicative, how it differs mechanistically and clinically from the concurrent treatment, and why both are medically necessary.

## Criteria-Mapping Structure

Address each element of UHC's duplicate-therapy rule directly. If the policy prohibits TMS concurrent with a specific other treatment, document the clinical rationale for the combination. If the policy is ambiguous, note the ambiguity and argue for the interpretation most favorable to coverage. An independent external reviewer will apply your plan's coverage terms and applicable clinical standards — a well-documented medical-necessity argument is your best tool.

## Next Step

File the internal appeal in writing before UHC's deadline. If the internal review upholds the denial, invoke external review in writing promptly — do not let the four-month window pass.